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Abstract
Background: Besides classical approaches for treating depression, physical activity has been demonstrated to be an
effective option. Bouldering psychotherapy (BPT) combines psychotherapeutic interventions with action-oriented
elements from the field of climbing. The aim of this study is to investigate the effectiveness of BPT compared with
a home-based exercise program (EP - active control group, superiority trial) and state-of-the-art cognitive
behavioural therapy (CBT – non-inferiority trial).
Methods: The study is being conducted as a multicentre randomised controlled intervention trial at three locations in
Germany. Participants are being randomised into three groups: BPT, CBT, or EP, each with a 10-week treatment phase.
A power analysis indicated that about 240 people should initially be included. The primary outcome of the study is
the Montgomery and Asberg Depression Rating Scale (MADRS) directly after the intervention. Additional measurement
points are located three, six, and 12months after the end of the intervention. The data are being collected via
computer-assisted telephone interviews. Statistical analyses comprise regression analyses to test for the superiority of
BPT over EP. To test for the non-inferiority of BPT and CBT, a non-inferiority margin of 1.9 points in the Patient Health
Questionnaire (PHQ-9) and two non-inferiority margins for the MADRS (half of the two smallest Cohen’s d values from
the current meta-analyses) was predefined. The mean difference between CBT and EP is being used as a
supplementary equivalence margin.
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Discussion: This is the first study to investigate the effect of a bouldering psychotherapy (BPT) on outpatients’ depressive
symptoms compared with mere physical activity (superiority analysis) and state-of-the-art cognitive behavioural therapy
(CBT, non-inferiority analysis).
Methodological strengths of the study are the elaborated, multicentred, randomised, controlled design. Assessors are
blinded with regard to group allocation which leads to high objectivity. The study is conducted in a naturalistic setting,
which leads to high external validity. Methodological limitations might be the clinical heterogeneity of the sample, which
may dilute the intervention effects.
Trial registration: ISRCTN12457760 (Registration date: 26 July 2017, retrospectively registered).
Keywords: Depression, Exercise program, Physical activity, Sports, Bouldering, Rock climbing, Psychotherapy
Background
With a lifetime prevalence of 12.5 [1] and a 12-month
prevalence of 3.2% [2], depression is one of the most
common diseases worldwide. Estimations of the WHO
indicate that by 2020, depression will be the second
leading cause of health impairment (after cardiovascular
diseases), and by 2030, it will be the most frequent im-
pairment in industrialised nations [3, 4]. In line with
clinical guidelines for the treatment of depression, medi-
cation and psychotherapy are the approaches that are
most commonly recommended [5, 6]. The gold standard
in the psychotherapeutic treatment of depression is cog-
nitive behavioural therapy. With effect sizes (Hedges’ g)
ranging from 0.55 to 0.98 (moderate to large effects) in
metaanalyses [7] it has shown to be at least as effective
as antidepressants [5, 8]. Especially regarding psycho-
therapy, there is a vast gap between supply and demand
owing to a lack of therapeutic resources. In the UK, only
10% of the people suffering from anxiety or depression
receive psychological treatment [9]. Another challenge is
that it is difficult to engage and retain patients in psy-
chological care. Only about 52.2% of depressive individ-
uals living in Germany actively seek professional help
[10]. Also in the UK, only half of the patients who re-
ceive psychological treatment from a general practitioner
attend two or more sessions [11]. These findings high-
light the need for new therapies that are as effective as
established treatment options and at the same time eas-
ier for patients to access, more attractive, and less stig-
matized. Besides the classical approaches of
psychotherapy and medication, physical activity has also
been demonstrated to be an effective treatment option
[12–15]. On the basis of effect sizes (Cohen’s d) that
have been reported to lie between 0.62 and 0.82 (moder-
ate to strong effects), physical activity has been added to
the German guidelines for the treatment of depression
as a supplementary therapeutic method [5].
One type of physical activity that has become increas-
ingly popular in recent years and is spreading all over
the world is climbing, notably bouldering. Bouldering
means climbing without a rope on rocks or artificial in-
door climbing walls at a height that permits the climber
to jump off. Climbing halls provide climbing routes with
different levels of difficulty (coded with different col-
ours), enabling persons with varying levels of physical
fitness to boulder together without feeling over- or un-
challenged. Climbing and bouldering have gained in-
creased attention in clinical practice and are nowadays
often used as part of the overall treatment plan for
health problems [16, 17]. Earlier research showed that
therapeutic climbing enables the stimulation of cogni-
tive, emotional, and physical development as well as
learning processes [18]. Furthermore, it can offer a
person an opportunity to become more active and can
be a learning opportunity in which a person can set real-
istic goals. Finally, mastering “bouldering problems” has
been found to have a positive impact on a climber’s
self-esteem [19]. Owing to the different levels of diffi-
culty, even beginners can experience a sense of achieve-
ment, which sets up positive reinforcement processes
that might be especially helpful in the treatment of de-
pression [18].
Existing studies on the therapeutic effects of climbing
and bouldering have suggested that climbing/bouldering
has positive effects on health issues such as chronic pain
[20–22], multiple sclerosis [23], cerebral palsy [24], and
severe haemophilia A [25] as well as on psychological
problems such as ADHD [19, 26], anxiety disorders [19],
and eating disorders [19]. Such effects might be moder-
ated by an increase in cognitive functioning [16, 19],
self-esteem, self-confidence, self-efficacy [19, 27], and so-
cial competences [16, 19]. Unfortunately, existing studies
have suffered from various methodological problems:
Some studies were case studies or descriptive reports
with low case numbers [16, 19, 28]; some used only
self-developed, unvalidated questionnaires or unstandar-
dised interviews [29]; most did not randomly assign par-
ticipants to intervention or control groups [30], and
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some used no control group at all [31]. Thus, a system-
atic review of existing randomised controlled studies on
climbing/bouldering for preventing and treating health
problems found only very low-quality evidence of
improvements through therapeutic climbing and led to
the conclusion that future studies should have a suffi-
cient sample size, should use patient important out-
comes, should be registered prospectively, and finally,
should be reported in accordance with the CONSORT
statement [31].
With respect to treating depression, some case re-
ports and observational studies have reported positive
effects of climbing and bouldering on depressive symp-
toms [16, 19, 30, 32]. Recently, a controlled – but not
randomised – trial including 40 in-patients suffering
from major depressive disorder showed the impact of
rock climbing on acute emotion regulation strategies
[17]. Positive affect and coping emotions significantly
increased, while negative affect and depressiveness sig-
nificantly decreased directly after the climbing session
in comparison with a relaxation control group. Between
2013 and 2015, our work group conducted a rando-
mised controlled pilot study to investigate the effect of
a bouldering intervention on depressive symptoms. A
total of 94 patients were randomly assigned to either a
waitlist control group or an intervention group, which
included eight sessions of bouldering psychotherapy.
Different health outcomes were assessed with standar-
dised psychological self-report questionnaires before
and after the eight-week intervention period as well as
16 weeks after the end of the therapy. Participants in
the intervention group reported a significant reduction
in depressive symptoms compared with the control
group, even when other types of physical activity was
controlled for [33, 34]. With an effect size (Cohen’s d)
of 0.77 (moderate effect) the effect of the bouldering
intervention on depressive symptoms was comparable
to other short-term group therapies [35] and to phys-
ical activity (see above).
Methods
Aims and hypothesis
The aim of the current study, StudyKuS (StudieKuS –
Klettern und Stimmung; engl. Climbing and Mood), is
to investigate a) whether our newly developed boulder-
ing psychotherapy is more effective in reducing depres-
sive symptoms than physical activity alone and b)
whether the effect of our therapy is comparable to
current state-of-the-art group psychotherapy. For this
purpose, we are comparing our bouldering psycho-
therapeutic intervention (BPT) with a state-of-the-art
cognitive behavioural group therapy (CBT) and a
home-based exercise program (EP - active control
group) using a randomised and controlled but never-
theless naturalistic design.
Research hypothesis
I. Bouldering psychotherapy (BPT) leads to a
significantly greater reduction in depressive
symptoms in outpatients with depression than
mere physical activity in the form of a home-based
exercise program (EP).
II. The positive effect of bouldering psychotherapy
(BPT) on reducing depressive symptoms in
outpatients with depression is not inferior to the
effect of cognitive-behavioural psychotherapy (CBT).
In this article, we describe the StudyKuS study proto-
col, which serves as a reference for forthcoming papers
that report the results of the study.
Study design and setting
To test the research hypotheses, a randomised, con-
trolled, multicentre, prospective longitudinal study with
three arms is being conducted. Recruiting for the
StudyKuS began in 2017 in three different regions in
Germany: a) the Erlangen/Nuremberg/Fuerth region
(metropolitan region of three cities), b) the Weyarn re-
gion (rural area surrounding Munich), and c) the Berlin
(capital) region. Each intervention is being carried out
by two therapists (with the exception of the EP, which
is supervised by the study’s headquarters) over a period
of 10 weeks in groups with a maximum of 11 partici-
pants. All of the three interventions in one region are
taking place during the same time period and are being
conducted in consecutive waves – with four waves in
the Erlangen/Nuremberg/Fuerth region as well as the
Weyarn region and two waves in the Berlin region. Par-
ticipants in one region and one wave are randomly allo-
cated to one of the three groups (BPT, CBT or EP).
Data are being collected via computer-assisted tele-
phone interviews (CATIs) before and directly after the
intervention as well as three, six, and 12 months after
the treatment. A data monitoring and safety board
(DMSB) is established (EG and JK) and supervises study
conduction and severe adverse events (SAEs). All
procedures have been approved by the Friedrich-Alex-
ander-Universität Erlangen-Nürnberg Ethics Commit-
tee (Ref. 360_16 B). The participant timeline is
presented in Fig. 1. Trial Registration Data are pre-
sented in Table 1 (ISRCTN12457760, Registration date:
26 July 2017, registered retrospectively).
Sample size estimation
A power analysis was computed on the basis of the au-
thors’ previous experience with the BPT in the pilot
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study in which a Cohen’s d of 0.77 was reached [33]. To
address Hypothesis I, a slightly lower effect size of 0.6
was assumed. Thus,61 patients will be needed in the
BPT group and 61 patients in the EP group (alpha = .05,
power = .9).
To address Hypothesis II, a non-inferiority margin of
1.9 points (SD = 3.8) on the PHQ-9 (as proposed in the
literature [36]) was used, which resulted in a total of 69
patients in the BPT group and 69 patients in the CBT
group (alpha = .05, power = .9). Thus, there should be 61
patients in the EP group, 69 patients in the BPT group,
and 69 patients in the CBT group, for a total of 199
patients. To account for dropouts between t0 and t1,
20% more patients are added (based on the drop-out-
rate of our pilot study), resulting in 40 additional pa-
tients for a total of 239.
Therefore, 10 waves in three therapy centres (two
waves in Berlin, four waves in Weyarn, four waves in
Erlangen) were planned. Each wave was designed to
include 24 participants on average, of which 20 were
expected to complete the respective intervention.
Also from the data of the pilot study, in which similar
recruitment modalities were applied, a failure of
approx. 40% of patients who do not meet the inclusion
criteria must be expected. This means that a total of
approximately 400 patients should be screened.
Fig. 1 Participant timeline. Abbreviations: BPT: bouldering psychotherapy; CBT: cognitive behavioural therapy; EP: exercise program; EQ-5D: EuroQol Five
Dimension Questionnaire; FERUS: Questionnaire on Resources and Self-Management Skills; FKB-20: Body Image Questionnaire; GAD-7: Generalized Anxiety
Disorder 7; GSE: General Self-Efficacy Scale; MADRS: Montgomery-Asberg Depression Rating Scale; PHQ-9: 9-Item Patient Health Questionnaire; R-SES:
Rosenberg Self-Esteem Scale; SCL-90: Symptom-Checklist; SD: Standard Deviation; VAS: visual analogue scale.
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Recruitment strategies
Subjects are being recruited in several ways: Informa-
tional material (e.g. flyer, posters) is being distributed
throughout the three study locations at psychiatric hos-
pitals, locally based psychotherapist offices, primary
care physician offices, pharmacies, and other psycho-
logical services (e.g. support groups). Information is
also being sent to psychotherapists, psychiatrists, and
primary care physicians requesting them to share it
with their patients. Prior to each interventional wave,
Table 1 Trial Registration Data
Data category Information
1. Primary registry and trial identification number ISRCTN12457760
2. Date of registration in
primary registry
26 July 2017
3. Secondary identifying numbers –
4. Source(s) of monetary or
material support
OH-DO-KWAN Stiftung Ludmilla Pankofer und Carl Wiedmeier
Förderverein Kletterzentrum Aufwärts in Miesbach e.V.
5. Primary sponsor OH-DO-KWAN Stiftung Ludmilla Pankofer und Carl Wiedmeier
6. Secondary sponsor(s) Förderverein Kletterzentrum Aufwärts in Miesbach e.V.
7. Contact for public queries see Point 8
8. Contact for scientific queries PD Dr. Katharina Luttenberger, katharina.luttenberger@uk-erlangen.de
9. Public title Study KuS (Klettern und Stimmung - Climbing and Mood), a combination of
bouldering and psychotherapy for treating depression
10. Scientific title Study KuS (Klettern und Stimmung - Climbing and Mood) - Prospective investigation
of the effectiveness of a combination of bouldering and psychotherapy in comparison
with an active control group and cognitive behavioural group therapy for patients
suffering from depression in an outpatient setting
11. Countries of recruitment Germany
12. Health condition(s) or
problem(s) studied
Depression
13. Intervention(s) Study arm 1: Intervention group receiving the combination of bouldering and psychotherapy
Study arm 2: Intervention group receiving cognitive-behavioural therapy
Study arm 3: Active control group
1.14. Key inclusion and
exclusion criteria
Ages eligible for study: adults;
Sexes eligible for study: both
Inclusion criteria:
1. Depression, measured by the patient’s score on the PHQ-9 (Cut-off ≥8)
2. Informed consent to participate in the study (especially regarding randomised
allocation and data acquisition)
3. Ability to come to the therapy locations
Exclusion criteria:
1. Acute suicidality
2. Severe psychiatric disorder (psychosis, mania, substance abuse)
3. Physical contraindication for climbing due to disorder or pregnancy
4. BMI < 17.5 or > 40
5. Age < 18 years
6. Actual participation in group psychotherapy
8. Began using psychiatric medication within the last 8 weeks
9. Began psychotherapy within the last 8 weeks
10. Planned inpatient stay during therapy
15. Study type Randomised controlled intervention study
16. Date of first enrollment June 2017
17. Target sample size 199
18. Recruitment status complete
19. Primary outcome(s) Depression measured using the score on an observer rating scale (Montgomery Asberg
Rating Scale, MADRS) by computer-assisted telephone interviews (CATI)
20. Key secondary outcomes e.g., body image, anxiety, social phobia, self-esteem, coping
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press releases are being issued and addressed to
different local newspapers and radio stations, and pre-
sentations are being given at local events (e.g. “Day of
Action against Depression”). On the web, a homepage
(http://www.psychiatrie.uk-erlangen.de/med-psycholo-
gie-soziologie/klettern-und-stimmung-die-studie-kus/)
and a Facebook account were created and are being up-
dated with current information regarding the study on
a regular basis.
Eligibility of participants
All individuals interested in the study are being invited
to attend information sessions held by the study
personnel, where they are provided with all relevant in-
formation about the conditions surrounding their
participation in the study (e.g. randomisation). People
who are willing to participate are asked to fill out a
short screening questionnaire (scanning for inclusion
and exclusion criteria) and to provide their written in-
formed consent.
Inclusion and exclusion criteria
To increase external validity, only a few inclusion and
exclusion criteria are being applied. Inclusion criteria
consist of acute depressive symptoms, informed consent
to participate in the study (especially regarding rando-
mised allocation and data acquisition), and the ability to
reach the therapy locations. The presence (or absence)
of depression is operationalised as a PHQ-9 score of at
least 8 points, ensuring a high level of sensitivity to all
depressive disorders [37]. Exclusion criteria are age
younger than under 18 years, a Body Mass index (BMI)
under 17.5 or over 40, contemporary participation in an-
other psychotherapeutic group therapy, started taking
psychiatric medication within the last 8 weeks (medica-
tion started before 8 weeks is not a reason for exclusion),
started individual psychotherapy within the last 8 weeks
(same as for medication), a planned inpatient stay during
the intervention period, physical contraindication for
bouldering (physical disorders or pregnancy), specific
psychiatric disorders (psychosis within the last 5 years, a
manic episode within the last 5 years, substance addic-
tion with substance abuse within the last year, Borderline
diagnosis with self-harming behaviour during the last
year), and acute suicidality. If it turns out that someone
is in a suicidal crisis, appropriate steps following good
clinical practice and a suicide risk management plan
should be taken by the study personnel, if necessary by
arranging for inpatient admission. For safety reasons, all
participants are obliged to sign an anti-suicide contract
for the duration of the study. All inclusion and exclusion
criteria are assessed via self-reports with the screening
questionnaire. In cases of unclear fulfilment of the inclu-
sion or exclusion criteria (especially regarding relevant
psychiatric diagnoses), potential participants are person-
ally interviewed by the study personnel.
Randomisation
All individuals meeting the inclusion criteria in one
study region are being randomised into one of the
three groups (BPT, CBT, EP). Randomisation is strati-
fied by sex and severity of depression according to the
PHQ-9 score from the screening questionnaire (9–14
mild, 15–19 moderate, 20–27 severe depression). After
randomisation, participants are informed about their allo-
cation and provided with all necessary information about
group participation. Randomisation is performed with a
computer-based system by the Institute of Medical In-
formatics, Biometrics, and Epidemiology (IMBE) of the
Friedrich-Alexander-Universität Erlangen-Nürnberg.
Masking
Participants know which treatment condition they are
in, but the interviewers who conduct the CATIs and
thus assess the outcomes of the study are blinded to
participants’ allocations. Prior to each interview, all par-
ticipants are reminded of the confidential nature of
their allocation and asked not to tell the interviewer
which treatment they receive.
Interventions
Bouldering psychotherapy (BPT)
Bouldering is defined as climbing to moderate heights
(up to around three metres) without the use of ropes or
harnesses. The great variety of difficulty levels in boul-
dering gyms (usually marked by different colours) al-
lows patients with different physical fitness levels to
easily boulder together in one group without feeling
over- or unchallenged. Our newly developed bouldering
intervention is a combination of bouldering and psy-
chotherapy and consists of 10 consecutive sessions of 2
hours, taking place in a bouldering gym once a week in
the late afternoon. The intervention takes place in a
group of about 10 patients who are supervised by two
climbing therapists. We have teams of two therapists in
each study region, but the compositions of personnel
may vary across the different waves of therapy because
the therapists are also balancing other commitments.
All in all, we engage nine climbing therapists for the
BPT groups. All but one of the climbing therapists are
either psychotherapists or are in the process of com-
pleting their psychotherapy hours (psychotherapists
must have a master degree in psychology plus an add-
itional 4200 h of further education as a psychotherapist
according to German law; the one exception has an
Master of Science in Health Science including sports
psychology) and are experienced in bouldering and
rock climbing (their climbing ability is rated at a
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minimum of grade 7 on the UIAA (Union Internation-
ale des Associations d’Alpinisme) scale; one person on
each team had received advanced training from the
German Alpine Association or the Austrian Institute
for therapeutic climbing). Prior to the intervention, all
of the therapists are thoroughly trained in bouldering
techniques, safety rules, and didactic elements by a pro-
fessional bouldering instructor and in the implementa-
tion of the bouldering therapy manual by two members
of the study’s headquarters, both of whom had obtained
qualifications in “therapeutic climbing”.
Each of the 10 sessions focuses on a specific psycho-
logical topic that we consider to be relevant in the devel-
opment and maintenance of depression. An overview of
the specific subjects covered in the 10 therapeutic ses-
sions is provided in Table 2.
To ensure a standardised implementation of the BPT
in all of the three therapy centres, the therapists follow a
BPT manual that includes a fixed schedule for each ses-
sion. Each session consists of three main parts: introduc-
tion (about 20 min.), action phase (about 75 min.), and
closure (about 25 min.). The introduction phase takes
place in an enclosed room (e.g. the yoga room) and be-
gins with a mindfulness exercise (e.g. breathing medita-
tion) to focus the patients’ attention on the current
moment, followed by the presentation of the topic of the
session and a brief exchange of patients’ experiences and
psychoeducation regarding the specific subject (e.g.
function and body signals of anxiety). Afterwards, pa-
tients are split into two smaller groups, and from then
on, each group is supervised by one therapist. The action
phase takes place in the bouldering hall and consists of
one to two subject-related bouldering exercises that are
supposed to evoke underlying emotions (e.g. anxiety),
unveil patients’ characteristic patterns (e.g. avoidance),
and - with the support of the therapists - enable patients
to engage in new experiences (e.g. exposition: bouldering
blindfolded). The remaining time in the action phase is
used for free bouldering, meaning that patients work on
their individual “projects” while supported by the thera-
pists. The closure phase takes part in the enclosed room
where all of the patients are reunited to talk about their
experiences during the bouldering exercises and to de-
velop ideas about how to integrate the lessons they
learned into their daily lives. Each session ends with a
body-related relaxation exercise.
Cognitive behavioural therapy (CBT)
The CBT group is also manualised and follows the treat-
ment plan of classical cognitive-behavioural therapy. It
combines the psychoeducational parts of Schaub et al.
[38] with specific exercises as well as elements of the
strategic behavioural therapy (SBT) by Sulz [39] and ele-
ments of the short-term concept by Hautzinger & Kisch-
kel [40]. At the beginning and end of each session,
mindfulness-based techniques and relaxation methods
are integrated. Comparable to the BPT, the CBT inter-
vention consists of 10 consecutive sessions of 2 hours,
takingplace once a week in the late afternoon in a group
of about 10 patients with teams of two therapists in each
study region (all in all, eight different therapists). Com-
parable to the qualification of the BPT therapists, all
CBT therapists are either psychotherapists or psycholo-
gists who are completing their psychotherapy hours and
are experienced in the treatment of depression. Prior to
the intervention, all of the therapists are thoroughly
trained in the implementation of the CBT manual by
two members of the study’s headquarters. Similar to the
BPT intervention, each of the 10 sessions focuses on a
specific psychological topic (see Table 3).
Therapists in all of the three therapy centres follow
a manual including a fixed schedule for each session.
Each session consists of three main parts – compar-
able to the BPT manual: a) introduction – which
consists of a mindfulness exercise, a short interactive
repetition of the last session, and a review of the
Table 2 Overview of the bouldering therapy sessions
Session Topic
1 Introduction to bouldering and mindfulness
2 Physical feeling and the body’s centre of gravity
3 Healthy handling of limitations
4 Expectations and standards
5 Self-efficacy, achievements, and pride
6 Self-esteem
7 Fear and trust I
8 Fear and trust II
9 Social relationships
10 Problem solving, reflecting on lessons learned, and
transferring them to daily life
Table 3 Overview of the cognitive behavioural therapy sessions
Session Topic
1 Introduction to CBT therapy and psychoeducation
2 Psychoeducation on depression and dysfunctional beliefs
3 Identifying and working on individual dysfunctional beliefs
4 Behavioural activation/ activity scheduling
5 Social relationships I
6 Social relationships II
7 Cognitive techniques I
8 Cognitive techniques II
9 Lessons learned: Transforming dysfunctional beliefs
10 Reflecting on lessons learned and on transferring them
to daily life
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home-based exercises; b) main part – in which the
specific topic is interactively developed using flip-
charts, exercise sheets, and small-group work; and c)
closure – where worksheets are handed out, home-
based exercises are discussed, and a relaxation exer-
cise (progressive muscle relaxation according to
Jacobsen) [41] is carried out.
Exercise program (EP)
The home-based Exercise Program consists of a 20-min
physical training program, which addresses the same
muscles used in bouldering or climbing. At the begin-
ning of the intervention, all participants receive a train-
ing manual (including instructions and explanations of
all of the exercises), a training DVD, training material
(e.g. a multifunctional latex band and training rings to
enhance finger and underarm power), as well as psy-
choeducational material explaining the link between
physical activity and mood. Participants are instructed to
engage in the training program on their own at home
approximately three times a week for the study period of
10 weeks. They receive reminders via e-mail to motivate
them to keep on exercising. At the midpoint of the
intervention (5 weeks), they are sent additional motiv-
ational material via postal mail. After 10 weeks, partici-
pants are asked how often they conducted the exercises.
After the second measurement point, former EP partici-
pants are offered the opportunity to participate in a sub-
sequent 10-week bouldering group, which follows the
same treatment plan as the BPT group.
Data collection
The collection of the outcome data is being conducted
via CATIs with the patients. The data are being collected
before the beginning of the intervention (t0), at the end
of the 10-week intervention period (t1), and 3 months
(t2), 6 months (t3), and 12 months (t4) after the end of
the intervention period. To prepare patients for the
interview, they are sent the questionnaire a few days be-
fore the interview takes place. The CATI interviewers
are clinical psychology students who are trained at the
study’s headquarters.
Measures
The measures employed at the different measurement
points are shown in Fig. 1.
Primary outcome measures
Montgomery-Asberg Depression Rating Scale (MADRS)
[42]. The MADRS is one of the most commonly used
rating scales for assessing the core symptoms of de-
pression [43]. It is conducted as a semi-structured
clinician-rated interview consisting of 10 items: appar-
ent sadness, reported sadness, inner tension, reduced
sleep, reduced appetite, concentration difficulties, las-
situde, inability to feel, pessimistic thoughts, and sui-
cidal thoughts. The items ask patients about their
experiences during the last week. Each item is rated
on a seven-point scale from zero to six with higher
scores indicating greater severity of symptoms. A
score greater than 31 on the MADRS indicates severe
depression, whereas a score of 10 or below indicates
remission [44, 45]. The interrater reliability is high
and it is sensitive to change [42]. Originally, the scale
was published without wording suggestions for clini-
cians to help them collect the information required to
rate the items. For this reason, we used the structured
interview guide for the Montgomery-Asberg Depression
Rating Scale (SIGMA) [43]. The SIGMA is a struc-
tured interview guide that offers a selection of differ-
ent questions for each of the 10 items with good to
excellent interrater reliabilities [43].
The 9-Item Patient Health Questionnaire (PHQ-9) [46,
47]. The PHQ-9 is a short self-assessment tool often
used in primary care settings to screen for depression
[48]. Its nine items cover the nine DSM-IV criteria and
are rated on a four-point scale ranging from zero (“not
at all”) to three (“nearly every day”). The items ask pa-
tients about their experiences during the last 2 weeks.
The total sum score suggests varying levels of depres-
sion. Scores from 0 to 4 indicate minimal depression,
scores from 5 to 9 mild depression, scores from 10 to
14 moderate depression, scores from 15 to 19 moder-
ately severe depression, and scores from 20 to 27 severe
depression [37, 46]. In the German validation study of
the PHQ-9 a cut-off point of 8 had the best relation of
sensitivity and specifity [37]. The PHQ-9 is well vali-
dated and sensitive to change [49].
Secondary outcome measures
EuroQol Five Dimension Questionnaire (EQ-5D) visual
analogue scale (VAS) [50]. The EQ-5D assesses health-
related quality of life. For the purpose of this study, we
included the VAS to ask patients to rate how good or
bad their health-related quality of life (HRQoL) is today.
The scale is numbered from zero (“worst HRQoL”) to
100 (“best HRQoL”). It was found to be practicable and
useful for the application in the general population [51].
Questionnaire on Resources and Self-Management
Skills (Fragebogen zur Erfassung von Ressourcen und
Selbstmanagementfähigkeiten, FERUS) [52]. The FERUS
assesses individuals’ health-related resources and man-
ageability. It consists of seven scales, but we included
only the coping subscale with 12 items. Items are rated
on a five-point Likert scale that ranges from one to five,
with higher test scores indicating good coping skills. All
scales of the FERUS have high convergent and
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discriminant validities and the retest reliabilities are
good to satisfying [52, 53].
Body Image Questionnaire (Fragebogen zum Körper-
bild, FKB-20) [54]. The FKB-20 assesses body image dis-
turbances and subjective aspects of body experience. It
consists of two subscales of 10 items each. For the pur-
pose of this study, we included only the vital body dy-
namics subscale. Each item is rated on a five-point scale
ranging from one (“strongly disagree”) to five (“strongly
agree”) with higher values indicating a more positive
body image. The statistical properties proved to be
satisfying [55].
Generalized Anxiety Disorder 7 (GAD-7) [47, 56]. The
GAD-7 is a brief self-reported questionnaire for asses-
sing generalized anxiety disorder. Patients are asked
how often they have felt bothered by each of the seven
core symptoms of generalized anxiety disorder during
the last 2 weeks. Items can be rated on a four-point
scale ranging from zero (“not at all”) to three (“nearly
every day”). Scores range from zero to 21, with scores
of ≥5, ≥ 10, and ≥ 15 indicating mild, moderate, and
severe anxiety symptoms, respectively. The GAD-7
proved to be a reliable and valid instrument [56].
General Self-Efficacy Scale (GSE) [57]. The GSE mea-
sures optimistic self-beliefs about coping with a variety
of difficult demands in life. Its 10 items can be rated on
a four-point scale ranging from one (“not at all true”)
to four (“exactly true”). The total score ranges from 10
to 40 with higher scores indicating higher self-efficacy.
The GSE has good psychometric properties [58].
Rosenberg Self-Esteem Scale (R-SES) [53, 59]. The
R-SES is a self-report instrument for evaluating global
self-worth by measuring both positive and negative
feelings about the self. Its 10 items can be answered on
a four-point scale ranging from zero (“strongly dis-
agree”) to three (“strongly agree”) with higher values in-
dicating stronger self-esteem. The psychometric
properties of the scale are satisfactory [60].
Symptom-Checklist (SCL-90). The SCL-90 is a self-re-
port inventory that is used to examine the global inten-
sity of psychological symptoms and distress experienced
during the past 7 days using a five-point Likert-type scale
ranging from zero to four. The SCL-90 covers nine
symptom dimensions, but for the purposes of this study,
we used only the interpersonal sensitivity subscale. Rat-
ings are summed for each subscale with higher scores
indicating greater severity of symptoms. The SCL-90 is a
reliable instrument and has satisfying convergent and
discriminant validities [61].
Other measures
Screening questionnaire The screening questionnaire
is filled out by individuals interested in participating in
the study after attending the informational sessions for
the purpose of assessing the inclusion and exclusion
criteria. It consists of sociodemographic data such as
age and gender as well as open questions that reflect
the criteria for inclusion and exclusion (e.g. height and
weight to calculate BMI, current therapeutic treatment,
physical limitations, psychiatric comorbidities, and de-
pressive symptoms as assessed with the PHQ-9).
The following data are being assessed via the CATIs in
addition to the questionnaires presented above:
Sociodemographic data (e.g. family status, level of
education).
Data regarding current occupation (e.g. ability to work,
current sick-leave status).
Medical history regarding depression (onset, duration,
and progression of depression).
Current therapeutic treatment (medical, psychological,
and drug treatment as well as inpatient treatment).
Critical life events during the past 6 months (e.g. death
of a relative).
Physical activity (frequency and kind of activity be-
yond activities included in the study).
Attitude towards physical activity (positive or negative
attitude).
Attitude towards future group allocation (EP, CBT,
BPT, comfortable, uncomfortable, no preference)
Avoidance behaviour On a self-developed five-point
scale ranging from zero (“not at all”) to four (“ex-
tremely”), we ask patients whether and how much they
avoid certain places, public transportation, special situa-
tions, or other.
Data quality management
All of the therapists and interviewers involved in the
study are thoroughly trained for their respective tasks
at the study’s headquarters. Therapists and interviewers
constantly remain in close contact with the study’s
headquarters and discuss all upcoming questions and
therapeutic progress in regular appointments. For ques-
tions or to eliminate uncertainties, the study headquar-
ters’ staff can be contacted anytime during the entire
study period. Treatment adherence is documented in
protocol assessment surveys, which are filled out by the
therapists after each session (e.g. deviations from the
manual, severe adverse events, and other extraordinary
events). To obtain evidence of the inter-rater reliability
of the SIGMA, 5% of the pre- (t0) and 5% of the post-
(t1) intervention data are being collected with the par-
ticipation of a second person who is observing. The
quality of the data is guaranteed by strict data monitor-
ing at the study’s headquarters over the entire period of
data collection.
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The patient information sheet contains a data protec-
tion declaration that is in accordance with European and
German data protection laws. Sensitive data collected
during the telephone interviews is pseudonymised and
stored in password-protected devices. Names and ad-
dresses of the participants are recorded separately and
password-protected. Patient information sheets and the
screening questionnaires are stored in a locked steel
cabinet. Only members of the study team have access to
the lists of the names and codes of participants. No
published material will contain patient identifying
information.
Data analysis
The data analyses will be performed with the “IBM
SPSS Statistics 21” software. In order to be able to as-
sess the quality of the randomisation, the baseline data
from the intervention and control groups will be exam-
ined for statistically significant differences. All data will
be checked for plausibility. Patients who drop out of
the study but are still available for the telephone inter-
views are being interviewed subsequently. A missing
data evaluation will be carried out, and missing values
will be imputed by EM-Imputation [62]. The main out-
come criterion is severity of depression assessed by the
MADRS. The primary data analytic strategy is “per
protocol” for the superiority trial and “intention to
treat” for the non-inferiority trial [63]. As a sensitivity
analysis, an additional analysis with “intention to treat”
for hypothesis 1 and “per protocol” for hypothesis 2 will
be performed. The level of statistical significance is set
at p = 0.05.
Hypothesis I: superiority of BPT over EP
The primary outcome variable is the MADRS. To test
the first hypothesis, t-tests for independent groups of
change scores (pre-post) will be performed between the
BPT and EP groups. In addition, multivariate analyses
(ANOVAs and multiple linear regression analyses) will
be calculated. To control for the effects of confounders,
demographic variables as well as other therapeutic treat-
ments patients used outside of the treatments offered in
the study (e.g. antidepressive medication, psychotherapy,
offers to participate in additional sports) will be included
in the regression analyses.
Hypothesis 2: non-inferiority of BPT to CBT
The second hypothesis will be tested by conducting a
non-inferiority analysis with both measurements for de-
pression, the PHQ-9, and the MADRS. The reason for
this is that a predefined equivalence margin for the
PHQ-9 already exists in literature, but this is not the
case for the MADRS. For the PHQ-9, we will use the
established equivalence margin of 1.9 points [36, 64].
For the MADRS, only two predefined equivalence mar-
gins can be found in the literature, both established for
medical treatment against placebo and not for CBT as in
our study [65, 66] .
Historical trials of cognitive behaviour group therapy
have yielded effect sizes of Cohen’s d ranging from 0.4
[67] to 0.68 [68] to 1.3 [35]. The non-inferiority margin
can be chosen as half of the mean difference between
state-of-the-art therapy and the control treatment [63,
69, 70]. Because it is easier to find non-inferiority if the
margin is larger, we will calculate it with the two lower
margins of 0.2 (0.5*0.4) and 0.34 (0.5*0.68) from the two
current meta-analyses. Therefore, we will calculate
Cohen’s d / Hedges’ g of the between-group difference
(BPT-CBT).
Furthermore, the difference between CBT and the ac-
tive control group EP will be calculated, and the mean
difference will be used as a supplementary non-inferior-
ity margin as proposed by different authors [63, 69, 70],
who suggest controlling for one’s own standard therapy
by using an additional control group if historical trials
for the estimation of the non-inferiority margin are
missing. Because our EP group is designed as an active
control group with a therapeutically active intervention
(physical activity), the margin found in the comparison
between CBT and EP is likely to be conservative com-
pared to an inactive control group. Various authors [63,
69, 71] recommend the definition of the margin based
on clinical considerations. At an average severity interval
of about 10 points (below 10 points remission, 10 to 20
points mild depression, to 31 points moderate depres-
sion [44, 45]), a reduction of at least 5 points appears
clinically relevant. The margin to be determined should
therefore not exceed 5 points.
Secondary measurements
Secondary outcome variables such as self-esteem and
anxiety will be tested exploratively with t-tests for inde-
pendent groups.
Discussion
This is the first study to investigate the effect of a boul-
dering psychotherapy (BPT) on outpatients’ depressive
symptoms compared with evaluated treatment options -
namely mere physical activity (superiority analysis) and
state-of-the-art cognitive behavioural therapy (CBT,
non-inferiority analysis).
The results of the study may contribute to an enlarge-
ment of treatment options for outpatients suffering from
depression. As bouldering is getting increasingly popular,
participation in a bouldering therapy might be more so-
cially accepted and thus may represent a lower
threshold-offering than participation in classical psycho-
therapeutic approaches.
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Participants of the study will probably benefit, as they
receive additional therapy without incurring additional
costs or wait times. All study arms were demonstrated
to be effective in the treatment of depression prior to
this study. Participants are free to start any additional
treatments offered by the German health care system
while participating in this study without suffering any
disadvantages from study personnel, and patients’ indi-
vidual ongoing treatment plans are not altered by their
participation in this study.
Participants in the BPT group have a slight risk of in-
juries, but this risk does not exceed the risks of other
physical activities. A study on injuries in sport-climbing
(which has higher risks of severe injuries than boulder-
ing) with about 2000 climbers revealed an average
number of 0.2 injuries per 1000 h of climbing [72]. In
our study, participants boulder for a maximum of 10*2
h in total. In our pilot study [33, 34], no SAEs in the
BPT occurred in around 2400 bouldering hours. Thus,
no serious injuries are expected. Nevertheless, SAEs
such as strains, ligament ruptures, or fractures as well
as suicidal attempts or actual suicides are documented
by the therapists for each group and interim analyses of
SAEs will be performed on a regular basis. If any ana-
lyses show a cumulation of SAEs in the BPT, being sig-
nificantly higher than in the CBT and the EP group, the
DMSB will be consulted.. If a causal connection with
the intervention can be plausibly established, the BPT
will be terminated and all patients will be offered CBT
instead. In addition, accident insurance is being in-
cluded in the trial participation for all patients. In case
of physical injuries during the BPT sessions, the af-
fected person will be stopped from bouldering and sent
to an appropriate specialist for medical clarification.
Suicidal thoughts between two sessions should be
shortly debriefed with the participant prior to the be-
ginning of the session and a suicidal assessment should
be carried out to decide whether the participant can
distance him- or herself from suicidal tendencies. In
case of a suicidal attempt, the participant will be hospi-
talized and excluded from the study.
All participants are asked to sign an anti-suicide con-
tract for the duration of the study in the screening
questionnaire. Interested persons who are not willing
or able to complete the anti-suicide contract are not in-
cluded in the study but are redirected to other treat-
ment options with higher intensity (e.g. inpatient
treatment). During the therapies, all therapists follow
good clinical practice in monitoring for suicide risk,
and suicide risk management plans in cases of acute
risk are established by the study centre.
Strengths of the study design are the randomisation,
the three study arms with evaluated treatment options
as active control groups and the longitudinal character
of the study with a long follow-up period of 1 year after
the end of treatment. The use of manualised treatments
in a naturalistic setting with recruitment of patients in
different regions throughout Germany (with a balanced
ratio of urban and rural regions) contributes to a high
internal and external validity of the study. In order to
be able to replicate and implement the treatment, it is
planned to publish the manual of the BPT if results of
the study show promise.
As our treatment is a non-drug therapy, it must be
given open-label and participants and therapists cannot
be blinded. In order to reach high objectivity of the re-
sults, CATI interviewers, who assess the outcome data
are blinded to group allocation of the participants.
We decided to allow patients to receive additional
care and defined only few in- and exclusion criteria.
This was due to ethical reasons, as we did not want to
disrupt ongoing treatment plans as well as to our ap-
proach of a naturalistic design. This however has the
disadvantage of clinical heterogeneity of the sample,
which may dilute the intervention effects.
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